Oxford Nanopore Technologies plc (LON:ONT)

Aerovate Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	183.19	169.67	198.6	133.66	113.86
Revenue Growth (YoY)	7.97%	-14.57%	48.59%	17.39%	118.70%
Cost of Revenue	77.8	79.19	74.79	60.47	66.98
Gross Profit	105.4	90.48	123.81	73.2	46.88
Selling, General & Admin	156.53	154.96	141.36	161.75	71.39
Research & Development	98.47	103.24	59.3	75.98	48.55
Other Operating Expenses	2.73	0.89	21.63	-	-
Operating Expenses	257.73	259.09	222.29	237.73	119.94
Operating Income	-152.33	-168.61	-98.48	-164.53	-73.06
Interest Expense	-3.57	-2.21	-1.63	-0.91	-0.75
Interest & Investment Income	14.84	18.85	5.94	0.22	0.09
Earnings From Equity Investments	-0.02	-0.23	-0.24	-0.06	-
Currency Exchange Gain (Loss)	-0.15	2.13	-5.43	0.5	0.56
EBT Excluding Unusual Items	-141.23	-150.07	-99.84	-164.78	-73.15
Gain (Loss) on Sale of Investments	1.27	0.3	-2.19	-1.23	-
Gain (Loss) on Sale of Assets	-	-	18.62	-	-
Pretax Income	-139.96	-149.77	-83.41	-166	-73.15
Income Tax Expense	6.23	4.74	7.61	1.61	-11.91
Net Income	-146.19	-154.51	-91.03	-167.61	-61.24
Net Income to Common	-146.19	-154.51	-91.03	-167.61	-61.24
Shares Outstanding (Basic)	898	834	824	732	705
Shares Outstanding (Diluted)	898	834	824	732	705
Shares Change (YoY)	7.66%	1.24%	12.54%	3.77%	21.23%
EPS (Basic)	-0.16	-0.19	-0.11	-0.23	-0.09
EPS (Diluted)	-0.16	-0.19	-0.11	-0.23	-0.09
Free Cash Flow	-123.83	-143.21	-72.46	-74.74	-79.54
Free Cash Flow Per Share	-0.14	-0.17	-0.09	-0.10	-0.11
Gross Margin	57.53%	53.33%	62.34%	54.76%	41.17%
Operating Margin	-83.16%	-99.38%	-49.59%	-123.10%	-64.17%
Profit Margin	-79.80%	-91.06%	-45.83%	-125.40%	-53.79%
Free Cash Flow Margin	-67.59%	-84.41%	-36.48%	-55.92%	-69.86%
EBITDA	-138.63	-150.43	-82.46	-151.59	-62.94
EBITDA Margin	-75.67%	-88.66%	-41.52%	-113.42%	-55.27%
D&A For EBITDA	13.71	18.18	16.02	12.94	10.13
EBIT	-152.33	-168.61	-98.48	-164.53	-73.06
EBIT Margin	-83.16%	-99.38%	-49.59%	-123.10%	-64.17%

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.